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Department of Medicine, Stanford University School of Medicine, Stanford, California, USACanagliflozin reduced kidney disease progression in
participants with type 2 diabetes in the CANagliflozin
cardioVascular Assessment Study (CANVAS) Program. This
analysis explored potential mediators of the effects of
canagliflozin on kidney outcomes. The percent mediating
effect of 18 biomarkers indicative of disease was determined
by comparing the hazard ratios for the effect of randomized
treatment from an unadjusted model and from a model
adjusting for the average post-randomization level of each
biomarker. Multivariable analyses assessed the joint effects of
biomarkers that mediated most strongly in univariable
analyses. The kidney outcome was defined as a composite of
40% estimated glomerular filtration rate decline, end-stage
kidney disease, or death due to kidney disease. Nine
biomarkers (systolic blood pressure [8.9% of effect explained],
urinary albumin:creatinine ratio [UACR; 23.9%], gamma
glutamyltransferase [4.1%], hematocrit [51.1%], hemoglobin
[41.3%], serum albumin [19.5%], erythrocytes [56.7%], serum
urate [35.4%], and urine pH [7.5%]) individually mediated the
effect of canagliflozin on the kidney outcome. In a
parsimonious multivariable model, erythrocyte concentration,
serum urate, and systolic blood pressure maximized
cumulative mediation (115%). Mediating effects of UACR, but
not other mediators, were highly dependent upon the
baseline level of UACR: UACR mediated 42% and 7% of the
effect in those with baseline UACR 30 mg/g or more and
under 30 mg/g, respectively. The identified mediators
support existing hypothesized mechanisms for the
prevention of kidney outcomes with sodium glucose co-
transporter 2 inhibitors. Thus, the disparity in mediating
effects across baseline UACR subgroups suggests that the
mechanism for kidney protection with canagliflozin may vary
across patient subgroups.
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T he CANagliflozin cardioVascular Assessment Study(CANVAS) Program reported that the sodium glucosecotransporter 2 (SGLT2) inhibitor canagliflozin reduces
the risk of clinically important kidney outcomes in patients
with type 2 diabetes with established cardiovascular disease or
those at high cardiovascular risk.1 SGLT2 inhibitors prevent
glucose and sodium from reabsorbing in the proximal tu-
bule,2 which promotes glycosuria and natriuresis and results
in improved glycemia, weight loss, blood pressure, and
albuminuria.3 These effects may explain individually or
jointly why canagliflozin confers long-term kidney benefits, as
observed in the CANVAS Program and subsequently
confirmed in the Canagliflozin and Renal Events in Diabetes
with Established Nephropathy Clinical Evaluation
(CREDENCE) trial.4–6
The mechanisms of action for kidney protection with
canagliflozin is an area of great interest. In epidemiologic
research, mediation analyses are used to investigate the
mechanism that underlies an observed effect of an interven-
tion on an outcome.7 The standard methodology quantifies
the degree of attenuation of the treatment effect on the
outcome of interest after inclusion of the mediator (i.e.,
biomarker) in the efficacy estimation model. Selection of
biomarkers for investigation as potential mediators may be
based on prior hypotheses, by systematically testing all
available biomarkers, or by some combination of the two. To
qualify as a potential mediator, a biomarker must be affected
both by the drug under investigation and associated with the
outcome of interest. However, even when these criteria are
met, the change in the biomarker does not always infer a
causal association.8
A recent mediation analysis of the effects of canagliflozin
suggested that uric acid, albuminuria, and markers of plasma
volume and hematopoiesis were the most important media-
tors for effects on heart failure.9 Whether the same or other
mediators underlie the long-term kidney protective effects of769
c l i n i ca l t r i a l JW Li et al.: Mediators of kidney protection of canagliflozincanagliflozin is unknown. The objective of the present ana-
lyses therefore was to explore potential mediators of the
beneficial effects of canagliflozin on major kidney outcomes
in the CANVAS Program.
RESULTS
The potential mediating effects of 21 biomarkers were
assessed, 18 of which were available for the entire CANVAS
Program and 3 of which were available for participants in the
CANVAS trial but not in CANVAS-Renal. For assessments of
average biomarker levels, the mean number of measurements
made is shown in Supplementary Table S1. The overall
average number of biomarker measurements was 14, and was
least for hematocrit, hemoglobin, erythrocytes, urine pH, and
ketones (mean, 8 measurements during the follow-up
period). The most biomarker measures were acquired for
blood pressure, pulse rate, weight, and body mass index
(mean, 19 measurements during the follow-up period).
Effects of canagliflozin compared with placebo on potential
mediators
There were clear effects of canagliflozin, compared with pla-
cebo, on multiple potential mediators of effect (Table 19 and
Supplementary Tables S2, S3, and S4): hemoglobin A1c,
fasting plasma glucose, systolic blood pressure (SBP), diastolic
blood pressure, weight, body mass index, urine pH, serum
bicarbonate, serum urate, serum gamma glutamyltransferase
(GGT), low-density lipoprotein cholesterol, high-density li-
poprotein cholesterol, total cholesterol, hematocrit, hemo-
globin, erythrocyte concentration, serum albumin, ketonuria,
and urinary albumin:creatinine ratio (UACR).
Associations of postrandomization levels of potential
mediators with risk of the composite kidney outcome
For 10 of the 18 potential mediators (SBP, triglycerides,
UACR, GGT, hematocrit, hemoglobin, serum albumin,
erythrocytes, serum bicarbonate, and serum urate) assessed in
the overall CANVAS Program, there was a significant asso-
ciation of the average postrandomization level with the risk of
kidney outcomes in the Cox proportional hazard regression
models (all P < 0.05) (Table 2). The supplementary analyses
of the biomarkers measured only in CANVAS identified
additional significant associations of the average follow-up
levels of urine pH with the risk of kidney outcomes
(Supplementary Table S2).
Estimated mediation of the effects of canagliflozin on kidney
outcome
For all 10 (1 in CANVAS alone) biomarkers modified by
canagliflozin versus placebo, there also were associations of
the biomarker changes with the subsequent risk of the kidney
outcome (SBP, triglycerides, UACR, GGT, hematocrit, he-
moglobin, serum albumin, erythrocytes, serum bicarbonate,
serum urate, and urine pH). Nine of these biomarkers were
identified as individually significant mediators of the effect of
canagliflozin on kidney outcome when the average post-
randomization levels were assessed in the primary models770(SBP, UACR, GGT, hematocrit, hemoglobin, serum albumin,
erythrocytes, serum urate, and urine pH). The 3 with the
largest magnitude of mediating effect were erythrocyte con-
centration (57%), hematocrit (51%), and hemoglobin (41%)
(Figure 1). Assessment of joint effects in a multivariable
model of the strongest 3 mediators representing different
modes of action resulted in the inclusion of erythrocyte
concentration, serum urate, and SBP, and an estimated cu-
mulative mediation of 115% (95% confidence interval [CI],
95–159) of the effects of canagliflozin on kidney outcome
(Figure 2).
For the early change in levels of potential mediators, there
were significant associations between potential mediators and
kidney outcome for 9 of the 18 biomarkers (Table 3 and
Supplementary Table S3). The same biomarkers identified as
possible mediators in the analyses of the average post-
randomization levels, with the exception of serum albumin,
were potential mediators in analyses of early change in the
biomarker of interest, although the magnitude of the medi-
ating effect in the early change analyses was somewhat smaller
(Table 3).
Subsidiary analyses based on the alternative counterfactual
framework, which aims to establish causal inferences in
epidemiologic research, identified 11 mediators based on
average levels (Supplementary Table S4). In the multivariable
model, inclusion of the average levels of erythrocyte con-
centration, serum urate, and UACR resulted in an estimated
overall mediation of 96% (95% CI, 92–104).
Mediating effects in patient subgroups
In subgroup analyses, mediating effects of biomarkers
generally were similar across patient subgroups, except for
UACR. In patients with a baseline UACR less than 30 mg/g,
the mediating effect of UACR was 7.4% (95% CI, 2.8–20.1),
whereas it was 42.3% (95% CI, 21.1–113.6) in patients with a
baseline UACR of 30 mg/g or greater (Figure 3). When me-
diators were assessed jointly, erythrocytes, serum urate, and
UACR were the strongest mediators in patients with a UACR
less than 30 mg/g, whereas in patients with a UACR of
30 mg/g erythrocytes or greater, UACR and body mass index
were the strongest mediators.DISCUSSION
We identified a large set of potential mediators of the effect of
canagliflozin on kidney outcomes. Some of the identified
mediators, such as UACR, were expected given the well-
established relationship between UACR changes and kidney
outcomes. Weak mediating effects were observed for SBP and
GGT, while hematocrit and hemoglobin, which may be
markers of volume and/or hematopoiesis, were identified
consistently as mediators across all analyses. Measures of
glycemic control were not identified as mediators. Mediating
effects of all biomarkers were consistent in patient subgroups,
except for UACR. UACR showed stronger mediating effects in
patients with increased UACR, suggesting that the underlyingKidney International (2020) 98, 769–777
Table 1 | Effects of canagliflozin on biomarkers that might mediate the effect of canagliflozin on kidney outcomes
Biomarker
Mean (SE) at baseline
Average difference (SE) at follow-up evaluationaPlacebo Canagliflozin
Glycemia
HbA1c, % 8.25 (0.01) 8.25 (0.01) –0.52 (0.02)
Vascular tone
SBP, mm Hg 136.90 (0.24) 136.44 (0.21) –3.91 (0.19)
DBP, mm Hg 77.81 (0.15) 77.62 (0.13) –1.33 (0.11)
Pulse rate, bpm 72.49 (0.16) 72.64 (0.14) –0.22 (0.12)
Lipids, mmol/l
LDL-Cb 2.30 (0.01) 2.29 (0.01) 0.11 (0.01)
HDL-Cb 1.18 (0.005) 1.18 (0.004) 0.05 (0.003)
Triglyceridesb 2.03 (0.02) 2.02 (0.02) 0.02 (0.02)
Total cholesterolb 4.37 (0.02) 4.35 (0.02) 0.16 (0.01)
Kidney
UACR, mg/gc 20.49 (315.41) 19.87 (288.54) –19% (–21%, –17%)
Adiposity
Weight, kg 90.01 (0.31) 90.28 (0.27) –2.20 (0.07)
BMI, kg/m2 31.97 (0.09) 31.95 (0.08) –0.79 (0.02)
GGT, U/l 37.74 (0.64) 38.37 (0.58) –4.34 (0.57)
Volume status and hematopoiesis
Hematocrit, % 41.96 (0.06) 42.00 (0.05) 2.53 (0.05)
Hemoglobin, g/l 139.09 (0.22) 139.54 (0.19) 7.65 (0.18)
Serum albumin, g/l 41.40 (0.05) 41.32 (0.04) 0.56 (0.04)
Erythrocytes, 1012/l 4.68 (0.01) 4.71 (0.01) 0.27 (0.01)
Indicators of acidosis/alkalosis
Serum bicarbonate, mmol/l 23.37 (0.04) 23.33 (0.03) –0.34 (0.03)
Other
Serum urate, mmol/l 349.78 (1.47) 348.21 (1.24) –23.49 (1.02)
BMI, body mass index; bpm, beats per minute; DBP, diastolic blood pressure; GGT, gamma glutamyltransferase; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; UACR, urinary albumin:creatinine ratio.
aMixed-model with repeated-measures analysis using all data available before completion in patients who had baseline and follow-up measurements for the respective
outcome. The model adjusted for region, baseline HbA1c, estimated glomerular filtration rate, BMI, baseline of the outcome, treatment, visit, and study subgroup
(CANagliflozin cardioVascular Assessment Study [CANVAS]/CANagliflozin cardioVascular Assessment Study–Renal [CANVAS-R]).
bFasting test results.
cBaseline data are the geometric mean (geometric coefficient of variation); differences are the percentage change from the adjusted geometric mean ratio (95% confidence
interval) obtained from a mixed-model with repeated-measures analysis applied on log-transformed data.
Bold indicates a significant effect at P < 0.05.
Reprinted in part from Li J, Woodward M, Perkovic V, et al. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail. 2020;8:57–
66.9 ª 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/ licenses/by-nc-nd/4.0/).
JW Li et al.: Mediators of kidney protection of canagliflozin c l i n i ca l t r i a lmechanism of kidney protection from canagliflozin may vary
by baseline UACR level.
Markers of volume status and erythropoiesis were strong
mediators in all models. SGLT2 inhibition causes a modest
natriuretic/diuretic effect,10 which results in modest re-
ductions in plasma volume and extracellular volume, as well
as increases in hematocrit and hemoglobin. Markers of vol-
ume status, including hematocrit and hemoglobin, have been
reported previously to be strong mediators of the beneficial
effects of SGLT2 inhibitors on cardiovascular death and heart
failure hospitalization.9,11 Fluid overload has been associated
with a higher risk of end-stage kidney disease in observational
studies.12,13 Correction of extracellular volume expansion
through natriuresis and diuresis, resulting in amelioration of
microcirculation in the kidney secondary to a reduction in
venous pressure and interstitial pressure, has some credence
as a mechanism by which SGLT2 inhibition may improve
kidney outcomes.14
In addition to volume reduction, increases in hematocrit
and hemoglobin also may reflect increased erythropoiesis.Kidney International (2020) 98, 769–777Dapagliflozin has been shown to transiently increase eryth-
ropoietin and red cell mass, indicating direct effects on
erythropoiesis that may improve kidney tissue oxygenation.15
Hypoxia in kidney tissues is a powerful predictor of adverse
long-term kidney outcomes, and stimulation of erythropoi-
esis is another plausible potential pathway for kidney pro-
tection with SGLT2 inhibition.
It also is possible that reducing albuminuria with SGLT2
inhibition is another route through which long-term kidney
protection is achieved. The underlying mechanism of the
albuminuria-lowering effects of SGLT2 inhibitors are not
completely understood, but reduction in intraglomerular
pressure secondary to restoration of tubuloglomerular feed-
back has been proposed to play an important role based on
findings in patients with type 1 diabetes.16 Whether such
findings equally apply to patients with type 2 diabetes is un-
certain because more recent data have suggested that acute
reductions in the glomerular filtration rate result from efferent
arterial vasodilation, possibly through inhibition of prosta-
glandins.17 Improvements in endothelial function or771
Table 2 | Observational associations of potential mediators
and the risk of the composite kidney outcomes
Effect of a 1-unit increase HR 95% CI P value
Glycemia
HbA1c, % 1.04 0.94–1.15 0.449
Vascular tone
SBP, mm Hg 1.02 1.01–1.03 <0.001
DBP, mm Hg 1.00 0.98–1.01 0.496
Pulse rate, bpm 1.00 0.99–1.01 0.884
Lipids, mmol/l
LDL-C 1.04 0.92–1.19 0.510
HDL-C 0.69 0.46–1.04 0.074
Triglycerides 1.33 1.05–1.69 0.017
Total cholesterol 1.06 0.96–1.17 0.269
Kidney
UACR, mg/g 1.81 1.69–1.93 <0.001
Adiposity
Weight, kg 1.01 1.00–1.01 0.131
BMI, kg/m2 1.02 1.00–1.04 0.073
GGT, U/l 1.34 1.13–1.58 <0.001
Volume status and hematopoiesis
Hematocrit, % 0.85 0.83–0.88 <0.001
Hemoglobin, g/l 0.96 0.95–0.97 <0.001
Serum albumin, g/l 0.81 0.79–0.83 <0.001
Erythrocytes, 1012/l 0.22 0.17–0.28 <0.001
Indicators of acidosis/alkalosis
Serum bicarbonate, mmol/l 0.92 0.88–0.96 <0.001
Others
Serum urate, mmol/l 1.01 1.01–1.01 <0.001
BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure;
GGT, gamma glutamyltransferase; HbA1c, hemoglobin A1c; HDL-C, high-density
lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol;
SBP, systolic blood pressure; UACR, urinary albumin:creatinine ratio.
Bold indicates a significant effect at P < 0.05.
c l i n i ca l t r i a l JW Li et al.: Mediators of kidney protection of canagliflozinendothelial glycocalyx function, which contribute to the
charge-selective properties of the glomerular basement mem-
brane, also may explain the albuminuria-lowering effects of
SGLT2 inhibitors.18 Regardless of the underlying mechanism,
reductions in albuminuria have been associated consistently
with reductions in long-term risk of kidney failure,19 and
decreasing albuminuria with canagliflozin also is likely to
contribute to protection against decreases in kidney function.
The disparity in mediating effects across subgroups
defined by baseline albuminuria suggests that the mechanism
of kidney protection may vary in patients with low versus
high degrees of albuminuria. The larger percentage of
mediation in the subgroup of patients with higher degrees of
albuminuria is consistent with the hypothesis that the
mechanism of the beneficial effect of canagliflozin in these
patients is through the decrease of albuminuria.20 However,
consistent kidney benefits for clinical outcomes with cana-
gliflozin also have been observed in normoalbuminuric par-
ticipants, suggesting alternate mechanisms.21 However, we
note that in all analyses the number of kidney outcomes in the
low-albuminuria subgroup was low, which may have pre-
cluded proper assessment of mediating effects in this sub-
group, and this finding warrants cautious interpretation.
Uric acid has been implicated in the progression of dia-
betic kidney disease through activation of the renin-
angiotensin-aldosterone system and proinflammatory
effects,22 and observational studies have shown that uric acid772may be an independent risk marker of chronic kidney disease
progression.23 Although these analyses support the notion
that the long-term protective effects of SGLT2 inhibition may
be mediated by reductions in uric acid, recent randomized
controlled trials of uric acid decreases with allopurinol have
not shown slowing of the progression of kidney function
decline in patients with chronic kidney disease or in patients
with type 1 diabetes.24,25
There was some evidence for mediation by measures of
acidosis, although not specifically for ketosis. It has been
hypothesized that, under persistent mild ketosis caused by
SGLT2 inhibition, there may be preferential uptake of
b-hydroxybutyrate by the kidney, thereby improving oxygen
consumption at the mitochondrial level.26 This may explain
recent findings of improved mitochondrial function in pa-
tients with type 2 diabetes receiving dapagliflozin.27 Imprecise
measurement of ketonuria and the collection of data in the
CANVAS trial alone reduced the power to test for a medi-
ating effect of ketosis in these analyses. The observed
reduction in urine pH and an associated mediating effect
may be owing to effects of canagliflozin on the sodium
hydrogen exchanger-3.28,29 Activity of the sodium hydrogen
exchanger-3 appears to be linked to SGLT2 activity in the
proximal tubule, which may explain in part the natriuretic
and diuretic effects of SGLT2 inhibition.
Overall, mediators of the effect of canagliflozin on kidney
outcomes overlapped with those observed previously for
heart failure.9 This is perhaps no surprise in light of the
strong interaction between kidney and heart failure. Because
the beneficial effects of canagliflozin on kidney function did
not mediate the effects on heart failure in our prior study, it is
likely that the identified mediators for kidney and heart
failure effects reflect common mechanistic pathways by which
canagliflozin exerts protection against these end points. We
note that the current analyses do not exclude other potential
mechanisms of benefit of canagliflozin, such as reductions in
oxidative stress, inflammation, and improvements in ischemic
reperfusion injury or mitochondrial function, which to some
extent could be even heart- or kidney-specific.30–32
These analyses of the CANVAS Program benefited from
the large size of the data set, the high quality of trial conduct,
the range of biomarkers available for analysis, the robust
adjudication of kidney outcomes, and the multiple methods
applied to assess mediation. However, there also were
important limitations. All of these investigations were per-
formed post hoc, and the results are best viewed as
hypothesis-generating, given the multiple statistical tests
performed. We were able to assess only the potential medi-
ating effects of biomarkers that were measured during the
trial, and it was not possible to assess the potential role of
pathways acting through other putative mechanisms directly,
such as inflammation, oxidative stress, arterial stiffness, or
vascular resistance. There also were significant challenges
inherent to the statistics underlying the methodologies
applied. First, an inherent limitation to all mediation analyses
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Figure 1 | Effects of univariable adjustment for potential mediators of the effect of canagliflozin on the composite kidney outcome.
Bold indicates a significant effect at P < 0.05. BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure;
GGT, gamma glutamyltransferase; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density
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Figure 2 | Effects of multivariable adjustment for potential mediators of the effect of canagliflozin on the composite kidney outcome.
Bold indicates a significant effect at P < 0.05. BMI, body mass index; CI, confidence interval; HR, hazard ratio; SBP, systolic blood pressure;
UACR, urinary albumin:creatinine ratio.
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Table 3 | Mediation analysis for potential mediators of the effect of canagliflozin on the composite kidney outcome when using






kidney events Mediation effect after adjustment in model
HR 95% CI P value
Events/




HbA1c, % –0.62 (0.02) 1.23 1.06–1.42 0.005 244/9868 0.64 (0.48–0.84) 9.7 –6.4 to 40.4
Vascular tone
SBP, mm Hg –3.58 (0.26) 1.02 1.01–1.03 0.003 249/10,002 0.64 (0.50–0.82) 9.5 2.2–24.9
DBP, mm Hg –1.52 (0.15) 1.02 1.00–1.03 0.080 249/10,002 0.61 (0.48–0.79) 3.1 –2.3 to 11.0
Pulse rate, bpm 0.06 (0.16) 1.00 0.99–1.02 0.829 249/10,001 0.60 (0.47–0.77) –0.2 –1.8 to 0.8
Lipids, mmol/l
LDL-Cc 0.09 (0.01) 1.02 0.84–1.24 0.825 228/9460 0.55 (0.42–0.72) –0.4 –3.0 to 2.0
HDL-Cc 0.04 (0.004) 0.55 0.27–1.14 0.109 228/9465 0.56 (0.43–0.73) 2.1 –2.5 to 7.7
Triglyceridesc –0.06 (0.02) 1.45 0.99–2.12 0.060 228/9463 0.56 (0.43–0.73) 1.5 –0.6 to 4.7
Total cholesterolc 0.11 (0.02) 1.04 0.88–1.21 0.671 228/9464 0.55 (0.42–0.72) –0.4 –3.2 to 2.4
Kidney
UACR, mg/gd –17% (–19%, –15%) 1.58 1.35–1.85 <0.001 236/9555 0.65 (0.50–0.85) 18.2 3.2–47.6
Adiposity
Weight, kg –1.33 (0.04) 1.01 0.95–1.07 0.718 248/9994 0.59 (0.45–0.76) –4.5 –21.1 to 17.0
BMI, kg/m2 –0.47 (0.02) 1.05 0.89–1.25 0.558 248/9981 0.59 (0.45–0.77) –3.3 –20.9 to 19.2
GGT, U/l –3.89 (0.50) 2.03 1.39–2.95 <0.001 249/9984 0.64 (0.49–0.82) 9.3 1.4–23.5
Volume status and hematopoiesis
Hematocrit, % 2.34 (0.07) 0.87 0.84–0.90 <0.001 222/9054 0.73 (0.56–0.97) 40.7 19.0–92.4
Hemoglobin, g/l 6.63 (0.22) 0.96 0.95–0.97 <0.001 223/9146 0.68 (0.52–0.89) 29.1 13.0–62.6
Serum albumin, g/l 0.59 (0.04) 0.88 0.83–0.93 <0.001 249/9984 0.63 (0.49–0.82) 8.3 –3.3 to 24.9
Erythrocytes, 1012/l 0.26 (0.01) 0.28 0.20–0.39 <0.001 223/9146 0.73 (0.55–0.97) 40.5 17.9–93.3
Indicators of acidosis/alkalosis
Serum bicarbonate, mmol/l –0.42 (0.05) 1.01 0.96–1.06 0.789 249/9981 0.60 (0.47–0.77) –0.1 –5.0 to 4.7
Other
Serum urate, mmol/l –23.21 (1.16) 1.01 1.00–1.01 <0.001 249/9984 0.68 (0.52–0.87) 19.0 9.5–46.7
BMI, body mass index; bpm, beats per minute; CI, confidence interval; DBP, diastolic blood pressure; GGT, gamma glutamyltransferase; HbA1c, hemoglobin A1c; HDL-C, high-
density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; UACR, urinary albumin:creatinine ratio.
aExpressed as mean (SE).
bMixed-model with repeated-measures analysis using all data available before completion in patients who had baseline and follow-up measurements for the respective
outcome. The model adjusted for region, baseline HbA1c, estimated glomerular filtration rate, BMI, baseline of the outcome, treatment, visit, and study subgroup
(CANagliflozin cardioVascular Assessment Study [CANVAS]/CANagliflozin cardioVascular Assessment Study–Renal [CANVAS-R]).
cFasting test results.
dBaseline data are the geometric mean (geometric coefficient of variation); differences are the adjusted geometric mean ratio (95% CI) obtained from mixed-model with
repeated-measures analysis applied on log-transformed data.
Bold indicates a significant effect at P < 0.05.
c l i n i ca l t r i a l JW Li et al.: Mediators of kidney protection of canagliflozinmediators are truly on the causal pathway to progression of
kidney disease rather than an epiphenomenon associated with
both the effects of canagliflozin and the future risk of kidney
disease. Second, it is possible that the identified mediators
may be reflections of progression of kidney disease, although
this assumption is less likely because the mediators were
affected differentially in the placebo and canagliflozin groups
and mediators in analyses of early change were similar to
mediators identified in analyses using the average post-
randomization level. Third, our analyses were limited by their
capacity to control for interactions between mediators and to
provide robust estimates of uncertainty. Specific findings also
were somewhat dependent on whether the standard or
counterfactual approach was taken, although results were
broadly similar. Assessing the joint effects of mediators
resulted in more than 100% of the effect being explained by
only 3 mediators, and this highlights the limited capacity to
explore and control for double counting of a mechanistic
pathway that is captured by more than 1 biomarker. It also is
possible that there are other mechanistic pathways that were774captured by none of the biomarkers included and for which
the magnitude of the mediating effect remains entirely un-
known. It should be noted that the composite kidney
outcome was driven by the sustained 40% decrease in the
estimated glomerular filtration rate component, and there
were few occurrences of end-stage kidney disease.
In conclusion, we identified a diverse set of potential
mediators of the effect of canagliflozin on kidney outcomes.
Some mediating effects were anticipated, others were not.
Our analyses provide some support for most of the hypoth-
esized mechanisms for the prevention of adverse kidney
outcomes with SGLT2 inhibitors.METHODS
The CANVAS Program integrated data from 2 randomized trials
(CANVAS and CANVAS-Renal) comparing the effects of canagli-
flozin versus placebo. The trials were scheduled for joint closeout
and analysis when at least 688 cardiovascular events had been
observed. All participants provided written informed consent, and








































Figure 3 | Percentage of the mediating effect of potential mediators of the effect of canagliflozin on the composite kidney outcome
across patient subgroups. BMI, body mass index; CI, confidence interval; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; UACR, urinary
albumin:creatinine ratio.
JW Li et al.: Mediators of kidney protection of canagliflozin c l i n i ca l t r i a lNCT01032629 and NCT01989754). All procedures followed were in
accordance with the Helsinki Declaration of 1964, as revised in 2013.
Participants
Participants were individuals with type 2 diabetes and an increased
cardiovascular risk.33 Participants were either 30 years of age or older
with a history of symptomatic atherosclerotic cardiovascular disease,
or 50 years of age or older with 2 or more of the following risk
factors for cardiovascular disease: duration of diabetes of at least 10
years, SBP higher than 140 mm Hg while receiving 1 or more
antihypertensive agents, current smoking, microalbuminuria or
macroalbuminuria, or a high-density lipoprotein cholesterol level of
less than 1 mmol/l (38.7 mg/dl). Participants were required to
have an estimated glomerular filtration rate at entry of more than
30 ml/min per 1.73 m2 of body surface area.
Randomization and study treatment
After a 2-week, single-blind, placebo run-in period, participants were
randomized centrally through an interactive web response system
using a computer-generated randomization schedule prepared by the
study sponsor using randomly permuted blocks. Participants in
CANVAS were assigned in a 1:1:1 ratio to canagliflozin 300 mg,
canagliflozin 100 mg, or matching placebo, and participants in
CANVAS-Renal were assigned randomly in a 1:1 ratio to canagli-
flozin or matching placebo, administered at an initial dose of 100 mg
daily with optional up-titration to 300 mg from week 13. Participants
and all study staff were masked to individual treatment allocations
until the completion of the study. Use of other background therapy
for glycemic and cardiovascular risk management was performed
according to best practice instituted in line with local guidelines.
Follow-up evaluation
Participants were followed up after randomization by face-to-face
follow-up evaluation with 3 visits scheduled in the first year and
further visits scheduled at 6-month intervals thereafter, with alter-
nating telephone follow-up evaluation and face-to-face assessments.Kidney International (2020) 98, 769–777The occurrence of hospitalization for kidney outcomes was evaluated
at every scheduled follow-up evaluation.
Outcomes
The outcome studied in this analysis was the composite outcome of a
sustained 40% reduction in the estimated glomerular filtration rate,
end-stage kidney disease, or death resulting from kidney disease. A
blinded end point committee independently adjudicated all potential
kidney outcomes using rigorous definitions that were prespecified
according to established criteria.34,35
Selection of potential mediators
A diverse set of biomarkers was measured at baseline and at multiple
time points during the follow-up period. The mediators initially
considered for investigation in this analysis were biomarkers that
were believed to likely be changed by treatment with canagliflozin
and associated with the risk of kidney outcomes. Potential mediators
were grouped into those likely acting through effects on glycemia,
vascular tone, lipids, kidney function, adiposity, volume status or
hematopoiesis, acid–base balance, and serum urate (Table 1). Fasting
plasma glucose level, urine pH, and ketonuria were measured in
CANVAS, but not CANVAS-Renal, and were assessed in subsidiary
analyses restricted to CANVAS participants. Ketonuria was assessed
as a dichotomous variable (none vs. trace or more), but all other
potential mediators were assessed as continuous measures.
Statistical analysis
The standard statistical method involves quantifying the effect of a
potential mediating variable on the primary association between the
exposure and the outcome of interest.36,37 If the inclusion of the
potential mediator in the primary model results in an attenuation of
the strength of the association between a drug and an outcome, this
is interpreted as the effect of the drug on the outcome being
mediated by the biomarker of interest. Another widely used
approach for assessment of mediation uses a product method.38 For
a biomarker to be eligible as a mediator, several conditions should be
fulfilled. First, canagliflozin compared with placebo should exert an775
c l i n i ca l t r i a l JW Li et al.: Mediators of kidney protection of canagliflozineffect on the biomarker of interest and, second, the post-
randomization level of the biomarker should be associated with the
risk of kidney outcomes.
The selection of potential mediators occurred on the basis of
establishing the effect of canagliflozin versus placebo on the potential
mediators usingmixedmodels incorporating repeatedmeasures of the
potential mediator. The between-group difference was assessed using
residual restricted maximum likelihood tests. The exception to this
approach was for the evaluation of ketonuria in CANVAS, which was
assessed using a logistic regressionmodel because urinary ketoneswere
recorded as a categoric variable. Associations of the potential mediator
with the kidney outcome were determined from Cox regression
models. In subsidiary analyses, the effect of canagliflozin relative to
placebo was determined on the early change in the potential mediator
by estimating the change in the potential mediator from baseline to
first postrandomization measurements, which variously was made
mainly between 6 and 18 weeks into the follow-up period.
Variables with skewed distributions were analyzed after log
transformation (triglycerides, UACR, GGT). Fasting plasma glucose
level, urine pH, and ketonuria were available only from CANVAS.
Individuals without a baseline measure of the mediator of interest
were excluded from the relevant analyses, as were individuals with no
follow-up measurement and those with a baseline measurement who
had kidney outcomes before a follow-up measurement was made.
The primary analyses were comparisons of hazard ratios from
Cox survival models for the association between randomized treat-
ment and the risk of kidney outcome, unadjusted and adjusted for
each biomarker in turn. In each case, the percentage mediation was





, where HRc is the hazard
ratio after adjustment for the biomarker and HR is the unadjusted
hazard ratio.39 The 95% CIs for the estimated percentage mediation
were obtained using a 5000-iteration bootstrap resampling proced-
ure. The combined potential mediating effect of multiple biomarkers
was quantified using the same equation. Multiple mediator models
were built by first selecting the biomarker with the largest percentage
mediation value. Each remaining biomarker then was included, in
turn, and the next biomarker that produced the greatest joint
mediation was added to the existing model. This was repeated until 3
mediators were added, with the mediation effect reaching 100%, or 4
mediators were added in the multivariable model. Only 1 variable
from each biomarker group was included in the multivariable
analysis because the goal was to capture different mechanistic pro-
cesses that were likely to mediate the effects of the drug.
To further test the robustness of the findings, we performed a
secondary analysis using the product method under the counter-
factual framework approach40 for univariable assessments, and using
nonlinear models (multiple additive regression trees and smoothing
splines) for multivariable assessments that were able to account for
collinearity between potential mediators. Briefly, the product
method under the counterfactual framework divides the overall ef-
fect of a treatment on an outcome determined from a Cox regression
model into direct and indirect components, which enables estima-
tion of the proportion of the effect mediated by the biomarker of
interest. For multivariable analysis based on linear models, correla-
tion among mediators can lead to estimates of effect mediation that
are greater than 100% and also may widen CIs. The use of nonlinear
models is more robust to overestimations caused by collinearities.41
For evaluation of the mediating effects of early effects of cana-
gliflozin, the statistical models were adjusted for the baseline value of
the biomarker to control for regression to the mean. Statistical776models exploring the long-term mediating effects by incorporating
the average biomarker level were not adjusted for the baseline value
because the baseline value already was included in the calculation of
the average effect. To further explore the impact of baseline values of
the potential mediator, mediation analyses were repeated in patient
subgroups defined by median values or clinically relevant thresholds.
All analyses were performed using SAS version 9.4 (SAS; Cary,
NC) and R studio version 1.1.463 (RStudio, Boston, MA). P values
less than 0.05 were deemed significant.
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